Publications
-
Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.
Carlsen TH,
Scheel TK, Ramirez S, Foung SK, Bukh J.
J Virol.
2013;
87
(3):
1385-99
-
Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry.
Kim S,
Ishida H, Yamane D, Yi M, Swinney DC, Foung S, Lemon SM.
J Virol.
2013;
87
(8):
4214-24
-
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.
Keck Z,
Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, Foung SK.
J Virol.
2013;
87
(1):
37-51
-
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY,
Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK.
PLoS Pathog.
2012;
8
(4):
e1002653
-
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.
Fofana I,
Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF.
Gastroenterology.
2012;
143
(1):
223-233.e9
-
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.
Potter JA,
Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH.
J Virol.
2012;
86
(23):
12923-32
-
Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry.
Liu Z,
Tian Y, Machida K, Lai MM, Luo G, Foung SK, Ou JH.
J Biol Chem.
2012;
287
(50):
41922-30
-
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.
Wang Y,
Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK.
J Biol Chem.
2011;
286
(51):
44218-33
-
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships.
Rychlowska M,
Owsianka AM, Foung SK, Dubuisson J, Bienkowska-Szewczyk K, Patel AH.
J Gen Virol.
2011;
92
(Pt 10):
2249-61
-
Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions.
Bianchi A,
Crotta S, Brazzoli M, Foung SK, Merola M.
Int J Hepatol.
2011:
2011
968161
-
Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.
Keck ZY,
Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK.
J Virol.
2011;
85
(20):
10451-63
-
Neutralizing antibody response to hepatitis C virus.
Wang Y,
Keck ZY, Foung SK.
Viruses.
2011;
3
(11):
2127-45
-
The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae.
Stapleton JT,
Foung S, Muerhoff AS, Bukh J, Simmonds P.
J Gen Virol.
2011;
92
(Pt 2):
233-46
-
The hepatitis C virus E1 glycoprotein undergoes productive folding but accelerated degradation when expressed as an individual subunit in CHO cells.
Botti V,
Bianchi A, Foung SK, Merola M.
PLoS One.
2011;
6
(8):
e23838
-
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.
Bankwitz D,
Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T.
J Virol.
2010;
84
(11):
5751-63
-
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.
Dhillon S,
Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid MN, Rychłowska M, Foung SK, Baumert TF, Angus AG, Patel AH.
J Virol.
2010;
84
(11):
5494-507
-
Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.
Sapparapu G,
Planque SA, Nishiyama Y, Foung SK, Paul S.
J Biol Chem.
2009;
284
(36):
24622-33
-
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.
Witteveldt J,
Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH.
J Gen Virol.
2009;
90
(Pt 1):
48-58
-
A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.
Keck ZY,
Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK.
J Virol.
2008;
82
(12):
6067-72
-
Antibody-dependent enhancement of hepatitis C virus infection.
Meyer K,
Ait-Goughoulte M, Keck ZY, Foung S, Ray R.
J Virol.
2008;
82
(5):
2140-9
-
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
Owsianka AM,
Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH.
J Gen Virol.
2008;
89
(Pt 3):
653-9
-
Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.
Keck ZY,
Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.
J Virol.
2008;
82
(12):
6061-6
-
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.
Machida K,
Kondo Y, Huang JY, Chen YC, Cheng KT, Keck Z, Foung S, Dubuisson J, Sung VM, Lai MM.
J Virol.
2008;
82
(13):
6711-20
-
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.
Gal-Tanamy M,
Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM.
Proc Natl Acad Sci U S A.
2008;
105
(49):
19450-5
-
Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein.
Iacob RE,
Keck Z, Olson O, Foung SK, Tomer KB.
Biochim Biophys Acta.
2008;
1784
(3):
530-42
-
Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies.
Keck ZY,
Machida K, Lai MM, Ball JK, Patel AH, Foung SK.
Curr Top Microbiol Immunol.
2008:
317
1-38
-
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.
Keck ZY,
Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, Luo G, Foung SK.
J Virol.
2007;
81
(2):
1043-7
-
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
Helle F,
Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C.
J Virol.
2007;
81
(15):
8101-11
-
Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6.
Machida K,
Cheng KT, Sung VM, Levine AM, Foung S, Lai MM.
J Virol.
2006;
80
(2):
866-74
-
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
Dreux M,
Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.
J Biol Chem.
2006;
281
(27):
18285-95
-
Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.
Eren R,
Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S.
J Virol.
2006;
80
(6):
2654-64
-
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.
Keck ZY,
Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J, Foung SK.
J Virol.
2005;
79
(21):
13199-208
-
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells.
Brazzoli M,
Helenius A, Foung SK, Houghton M, Abrignani S, Merola M.
Virology.
2005;
332
(1):
438-53
-
Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide.
Taguchi H,
Keck Z, Foung SK, Paul S, Nishiyama Y.
Bioorg Med Chem Lett.
2004;
14
(17):
4529-32
-
Characterization of functional hepatitis C virus envelope glycoproteins.
Op De Beeck A,
Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J.
J Virol.
2004;
78
(6):
2994-3002
-
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
Keck ZY,
Op De Beeck A, Hadlock KG, Xia J, Li TK, Dubuisson J, Foung SK.
J Virol.
2004;
78
(17):
9224-32
-
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.
Keck ZY,
Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, Lai MM, Foung SK.
J Virol.
2004;
78
(13):
7257-63
-
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein.
Heo TH,
Chang JH, Lee JW, Foung SK, Dubuisson J, Kang CY.
J Immunol.
2004;
173
(1):
446-55
-
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2.
Lozach PY,
Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R.
J Biol Chem.
2003;
278
(22):
20358-66
-
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody.
Cocquerel L,
Quinn ER, Flint M, Hadlock KG, Foung SK, Levy S.
J Virol.
2003;
77
(2):
1604-9
-
Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
Hadlock KG,
Yang Q, Rowe J, Foung SK.
AIDS Res Hum Retroviruses.
2002;
18
(1):
57-70
-
Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
Triyatni M,
Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ.
Virology.
2002;
298
(1):
124-32
-
Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
Hadlock KG,
Gish R, Rowe J, Rajyaguru SS, Newsom M, Warford A, Foung SK.
J Med Virol.
2001;
65
(1):
23-9
-
The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis.
Quinn ER,
Chan CH, Hadlock KG, Foung SK, Flint M, Levy S.
Blood.
2001;
98
(13):
3745-9
-
V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen.
Chan CH,
Hadlock KG, Foung SK, Levy S.
Blood.
2001;
97
(4):
1023-6
-
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
Hadlock KG,
Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK.
J Virol.
2000;
74
(22):
10407-16
-
The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
Hadlock KG,
Rowe J, Foung SK.
J Virol.
1999;
73
(2):
1205-12
-
Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia.
Loughran TP,
Hadlock KG, Perzova R, Gentile TC, Yang Q, Foung SK, Poiesz BJ.
Br J Haematol.
1998;
101
(2):
318-24
-
Experimental infection of chimpanzees with hepatitis G virus and genetic analysis of the virus.
Bukh J,
Kim JP, Govindarajan S, Apgar CL, Foung SK, Wages J, Yun AJ, Shapiro M, Emerson SU, Purcell RH.
J Infect Dis.
1998;
177
(4):
855-62
-
GBV-C/HGV: a new virus within the Flaviviridae and its clinical implications.
Hadlock KG,
Foung SK.
Transfus Med Rev.
1998;
12
(2):
94-108
-
Large granular lymphocyte leukaemia occurring after renal transplantation.
Gentile TC,
Hadlock KG, Uner AH, Delal B, Squiers E, Crowley S, Woodman RC, Foung SK, Poiesz BJ, Loughran TP.
Br J Haematol.
1998;
101
(3):
507-12
-
Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.
Hadlock KG,
Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, Yang J, Gascon R, Halmos J, Rehman SM, McGrath MS, Foung SK.
J Virol.
1997;
71
(8):
5828-40
-
Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes.
Loughran TP,
Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, Foung SK, Poiesz BJ.
Blood.
1997;
90
(5):
1977-81
-
A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
Arp J,
LeVatte M, Rowe J, Perkins S, King E, Leystra-Lantz C, Foung SK, Dekaban GA.
J Virol.
1996;
70
(11):
7349-59
-
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent.
Linnen J,
Wages J, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JW, Young L, Piatak M, Hoover C, Fernandez J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SK, Thomas H, Bradley D, Margolis H, Kim JP.
Science.
1996;
271
(5248):
505-8
-
Delineation of an immunodominant and human T-cell lymphotropic virus (HTLV)-specific epitope within the HTLV-I transmembrane glycoprotein.
Hadlock KG,
Goh CJ, Bradshaw PA, Perkins S, Lo J, Kaplan JE, Khabbaz R, Foung SK.
Blood.
1995;
86
(4):
1392-9
-
Enhanced specificity of truncated transmembrane protein for serologic confirmation of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections by western blot (immunoblot) assay containing recombinant envelope glycoproteins.
Varma M,
Rudolph DL, Knuchel M, Switzer WM, Hadlock KG, Velligan M, Chan L, Foung SK, Lal RB.
J Clin Microbiol.
1995;
33
(12):
3239-44
-
Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation by electrofusion.
Perkins S,
Foung SK.
Methods Mol Biol.
1995:
48
295-307
-
Immunoglobulin prophylaxis against human T cell lymphotropic virus type II in rabbits.
Morishita N,
Ishii K, Tanaka Y, Sawada T, Hoshino H, Foung SK, Miyoshi I.
J Infect Dis.
1994;
169
(3):
620-3
-
Localization of antigenic sites on human cytomegalovirus virion structural proteins encoded by UL48 and UL56.
Bradshaw PA,
Duran-Guarino MR, Perkins S, Rowe JI, Fernandez J, Fry KE, Reyes GR, Young L, Foung SK.
Virology.
1994;
205
(1):
321-8
-
Amplification and detection of a single molecule of human immunodeficiency virus RNA.
Nakamura S,
Katamine S, Yamamoto T, Foung SK, Kurata T, Hirabayashi Y, Shimada K, Hino S, Miyamoto T.
Virus Genes.
1993;
7
(4):
325-38
-
Association of '(tropical) ataxic neuropathy' with HTLV-II.
Sheremata WA,
Harrington WJ, Bradshaw PA, Foung SK, Raffanti SP, Berger JR, Snodgrass S, Resnick L, Poiesz BJ.
Virus Res.
1993;
29
(1):
71-7
-
Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II.
Roberts BD,
Foung SK, Lipka JJ, Kaplan JE, Hadlock KG, Reyes GR, Chan L, Heneine W, Khabbaz RF.
J Clin Microbiol.
1993;
31
(2):
260-4
-
Human T lymphotropic virus type I/II in Lake Lindu Valley, Central Sulawesi, Indonesia.
Lal RB,
Lipka JJ, Foung SK, Hadlock KG, Reyes GR, Carney WP.
J Acquir Immune Defic Syndr.
1993;
6
(9):
1067-8
-
Isotypic and IgG subclass restriction of the humoral immune responses to human T-lymphotropic virus type-I.
Lal RB,
Buckner C, Khabbaz RF, Kaplan JE, Reyes G, Hadlock K, Lipka J, Foung SK, Chan L, Coligan JE.
Clin Immunol Immunopathol.
1993;
67
(1):
40-9
-
Neutralizing antibody to vesicular stomatitis virus (HTLV-I) pseudotype in infants born to seropositive mothers.
Iwahara Y,
Sawada T, Taguchi H, Hoshino H, Umemoto M, Take H, Foung S, Miyoshi I.
Jpn J Cancer Res.
1993;
84
(2):
114-6
-
Spastic ataxia associated with human T-cell lymphotropic virus type II infection.
Harrington WJ,
Sheremata W, Hjelle B, Dube DK, Bradshaw P, Foung SK, Snodgrass S, Toedter G, Cabral L, Poiesz B.
Ann Neurol.
1993;
33
(4):
411-4
-
Cloning and analysis of a recombinant antigen containing an epitope specific for human T-cell lymphotropic virus type II.
Hadlock KG,
Lipka JJ, Chow TP, Foung SK, Reyes GR.
Blood.
1992;
79
(10):
2789-96
-
Immune responsiveness to the immunodominant recombinant envelope epitopes of human T lymphotropic virus types I and II in diverse geographic populations.
Buckner C,
Roberts CR, Foung SK, Lipka J, Reyes GR, Hadlock K, Chan L, Gongora-Biachi RA, Hjelle B, Lal RB.
J Infect Dis.
1992;
166
(5):
1160-3
-
Serologic confirmation of simian T-lymphotropic virus type I infection by using immunoassays developed for human T-lymphotropic virus antibody detection.
Rudolph DL,
Yee J, Mone J, Foung SK, Lipka JJ, Reyes GR, Hadlock K, Chan L, Villinger F, Lairmore MD.
J Clin Microbiol.
1992;
30
(4):
858-61
-
Antibodies to hepatitis C virus in low-risk blood donors: implications for counseling positive donors.
Hsu HH,
Gonzalez M, Foung SK, Feinstone SM, Greenberg HB.
Gastroenterology.
1991;
101
(6):
1724-7
-
HTLV-I-associated myelopathy in a Californian: diagnosis by reactivity to a viral recombinant antigen.
Honig LS,
Lipka JJ, Young KY, Weiss JH, Foung SK.
Neurology.
1991;
41
(3):
448-50
-
Modified Western blot assay for confirmation and differentiation of human T cell lymphotropic virus types I and II.
Lipka JJ,
Santiago P, Chan L, Reyes GR, Samuel KP, Blattner WA, Shaw GM, Hanson CV, Sninsky JJ, Foung SK.
J Infect Dis.
1991;
164
(2):
400-3
-
Parameters to enhance human hybridoma formation with hypoosmolar electrofusion.
Perkins S,
Zimmermann U, Foung SK.
Hum Antibodies Hybridomas.
1991;
2
(3):
155-9
-
Significance of human T-lymphotropic virus type I indeterminant serological findings among healthy individuals.
Lipka JJ,
Young KK, Kwok SY, Reyes GR, Sninsky JJ, Foung SK.
Vox Sang.
1991;
61
(3):
171-6
-
Low incidence of HTLV infections in random blood donors with indeterminate western blot patterns.
Kwok S,
Lipka JJ, McKinney N, Kellogg DE, Poiesz B, Foung SK, Sninsky JJ.
Transfusion.
1990 Jul-Aug;
30
(6):
491-4
-
Development of microfusion techniques to generate human hybridomas.
Foung S,
Perkins S, Kafadar K, Gessner P, Zimmermann U.
J Immunol Methods.
1990;
134
(1):
35-42
-
Efficient hybridization of mouse-human cell lines by means of hypo-osmolar electrofusion.
Zimmermann U,
Gessner P, Schnettler R, Perkins S, Foung SK.
J Immunol Methods.
1990;
134
(1):
43-50
-
Generation of a human hybridoma producing a pure anti-HLA-A2 monoclonal antibody.
Wallace EF,
Foung SK, Bradbury K, Pask SL, Grumet FC.
Hum Immunol.
1990;
28
(1):
65-9
-
Electric field-induced cell fusion and human monoclonal antibodies.
Foung SK,
Perkins S.
J Immunol Methods.
1989;
116
(1):
117-22
-
Human monoclonal antibodies to human cytomegalovirus.
Foung SK,
Perkins S, Bradshaw P, Rowe J, Rabin LB, Reyes GR, Lennette ET.
J Infect Dis.
1989;
159
(3):
436-43
-
Initial identification and mapping of distinct Rh0 (D) epitopes.
Rodriguez L,
Winn L, Foung SK.
Rev Fr Transfus Immunohematol.
1988;
31
(2):
223-31
-
The efficacy of PlA1-negative platelet transfusion therapy in posttransfusion purpura.
Lippman SM,
Lizak GE, Foung SK, Grumet FC.
West J Med.
1988;
148
(1):
86-8
-
Human monoclonal anti-T cell antibody from a patient with juvenile rheumatoid arthritis.
Alpert SD,
Turek PJ, Foung SK, Engleman EG.
J Immunol.
1987;
138
(1):
104-8
-
Human monoclonal antibodies to Rh0(D).
Foung SK,
Blunt JA, Wu PS, Ahearn P, Winn LC, Engleman EG, Grumet FC.
Vox Sang.
1987;
53
(1):
44-7
-
A human monoclonal antibody to rhG.
Foung SK,
Blunt J, Perkins S, Winn L, Grumet FC.
Vox Sang.
1986;
50
(3):
160-3
-
A monoclonal antibody against HLA-A11 and A24.
Foung SK,
Taidi B, Ness D, Grumet FC.
Hum Immunol.
1986;
15
(3):
316-9
-
Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection.
Arvin AM,
Koropchak CM, Williams BR, Grumet FC, Foung SK.
J Infect Dis.
1986;
154
(3):
422-9
-
Generation of human monoclonal antibodies by fusion of EBV-activated B cells to a human-mouse hybridoma.
Foung SK,
Engleman EG, Grumet FC.
Methods Enzymol.
1986:
121
168-74
-
A new approach to the diagnosis of active Rh0(D) immunization in passively immunized pregnant women.
Foung SK,
Perkins S, McCallum WD, Tom S, Engleman EG, Grumet FC.
Vox Sang.
1985;
49
(3):
206-10
-
Human monoclonal antibodies against group A red blood cells.
Raubitschek A,
Senyk G, Larrick J, Lizak G, Foung S.
Vox Sang.
1985;
48
(5):
305-8
-
Human monoclonal antibodies neutralizing varicella-zoster virus.
Foung SK,
Perkins S, Koropchak C, Fishwild DM, Wittek AE, Engleman EG, Grumet FC, Arvin AM.
J Infect Dis.
1985;
152
(2):
280-5
-
Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma.
Foung SK,
Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC.
J Immunol Methods.
1984;
70
(1):
83-90
-
Monoclonal antibody (B27M2) subdividing HLA-B27.
Grumet FC,
Fendly BM, Fish L, Foung S, Engleman EG.
Hum Immunol.
1982;
5
(1):
61-72
-
Production of functional human T-T hybridomas in selection medium lacking aminopterin and thymidine.
Foung SK,
Sasaki DT, Grumet FC, Engleman EG.
Proc Natl Acad Sci U S A.
1982;
79
(23):
7484-8
-
Eosinophilia in children.
Foung S,
Glader BE.
Pediatr Ann.
1979;
8
(6):
39-51
-
The effects of starvation and refeeding on muscle protein synthesis and catabolism in the young rat.
Ogata ES,
Foung SK, Holliday MA.
J Nutr.
1978;
108
(5):
759-65
Navigation for This Section: Stanford Hospital & Clinics
Additional Links: Hospital Services
FIND A PHYSICIAN
Help